AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safe ...

Alpha Bella (Justify)–who was scratched from last Saturday's GII Buena Vista on turf in favor of this weekend's GI B. Wayne Hughes Beholder Mile on dirt–and royally-bred Eagles Flight (Curlin) were ...

A consortium argues that GDC could not purport to terminate the procurement proceedings at the tail end without the risk of ...

Michael McCarthy enjoyed the kind of day most trainers could only wish for last Saturday at Santa Anita. He won four races on an 11-race card including the GI Frank E. Kilroe Mile with Formidable Man ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF ...

Systematic review finds that while low-dose fluoride has little effect on gut microbiota, high doses disrupt microbial ...

Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, ...

Facteus, the #1 provider of consumer transaction data and insights, today announced the release of Onyx, an untapped, industry-leading dataset of over $400B in annual consumer purchases across more ...